Professor | Xiaojing Zhang | Asia Growth Partners

	Upload Avatar (500 x 500)
Name	Xiaojing Zhang
Contact Information	zhangxjing@whu.edu.cn
Language ability	Chinese, English
Province	Hubei

Upload Avatar (500 x 500)

Name

Xiaojing Zhang

Contact Information

zhangxjing@whu.edu.cn

Language ability

Chinese, English

Province

Hubei

University/Lab Affiliation and Title	Wuhan University
Faculty	Medical School
Academic Background & Achievements	2005-2009 Bachelor in Pharmaceutical Engineering, Beijing University of Chinese Medicine 2009-2012 Master in Natural Medicinal Chemistry, Peking University Health Science Center 2012-2016 PhD in Biopharmaceuticals, University of Macau
Work Experience	2016-2019 Assistant Researcher, Central Laboratory, Wuhan University People's Hospital 2020-2021 Distinguished Researcher, Animal Experiment Center, Wuhan University 2021-present Distinguished Researcher, School of Basic Medical Sciences, Wuhan University

University/Lab Affiliation and Title

Wuhan University

Faculty

Medical School

Academic Background & Achievements

2005-2009 Bachelor in Pharmaceutical Engineering, Beijing University of Chinese Medicine
2009-2012 Master in Natural Medicinal Chemistry, Peking University Health Science Center
2012-2016 PhD in Biopharmaceuticals, University of Macau

Work Experience

2016-2019 Assistant Researcher, Central Laboratory, Wuhan University People's Hospital
2020-2021 Distinguished Researcher, Animal Experiment Center, Wuhan University
2021-present Distinguished Researcher, School of Basic Medical Sciences, Wuhan University

Areas of Focus	Mechanisms of acute and chronic liver injury and drug development Pathological mechanisms of non-alcoholic fatty liver disease and related liver metabolic diseases and drug development Core drivers of multi-organ damage caused by ischemia-reperfusion and drug development
Publications	The Neutrophil-to-Lymphocyte Ratio Determines Clinical Efficacy of Corticosteroid Therapy in Patients with COVID-19, Zhang XJ, et al., 2021 Non-alcoholic fatty liver disease: a metabolic burden promoting atherosclerosis, Zhang XJ, et al., 2020 Low-Dose Sorafenib Acts as a Mitochondrial Uncoupler and Ameliorates Nonalcoholic Steatohepatitis, Zhang XJ, et al., 2020 Hepatic IRF2BP2 Mitigates Nonalcoholic Fatty Liver Disease by Directly Repressing the Transcription of ATF3, Zhang XJ, et al., 2020 Integrated Omics Reveals Tollip as a Regulator and Therapeutic Target for Hepatic Ischemia-Reperfusion Injury in Mice, Zhang XJ, et al., 2019 In-Hospital Use of Statins Is Associated with a Reduced Risk of Mortality among Individuals with COVID-19, Zhang XJ, et al., 2020 An ALOX12–12-HETE–GPR31 signaling axis is a key mediator of hepatic ischemia-reperfusion injury, Zhang XJ, et al., 2018 Time to step-up the fight against NAFLD, Zhang XJ, et al., 2018 Targeting CASP8 and FADD-like apoptosis regulator ameliorates nonalcoholic steatohepatitis in mice and nonhuman primates, Zhang XJ, et al., 2017 The E3 ligase tripartite motif 8 targets TAK1 to promote insulin resistance and steatohepatitis, Zhang XJ, et al., 2017

Areas of Focus

Mechanisms of acute and chronic liver injury and drug development
Pathological mechanisms of non-alcoholic fatty liver disease and related liver metabolic diseases and drug development
Core drivers of multi-organ damage caused by ischemia-reperfusion and drug development

Publications

The Neutrophil-to-Lymphocyte Ratio Determines Clinical Efficacy of Corticosteroid Therapy in Patients with COVID-19, Zhang XJ, et al., 2021
Non-alcoholic fatty liver disease: a metabolic burden promoting atherosclerosis, Zhang XJ, et al., 2020
Low-Dose Sorafenib Acts as a Mitochondrial Uncoupler and Ameliorates Nonalcoholic Steatohepatitis, Zhang XJ, et al., 2020
Hepatic IRF2BP2 Mitigates Nonalcoholic Fatty Liver Disease by Directly Repressing the Transcription of ATF3, Zhang XJ, et al., 2020
Integrated Omics Reveals Tollip as a Regulator and Therapeutic Target for Hepatic Ischemia-Reperfusion Injury in Mice, Zhang XJ, et al., 2019
In-Hospital Use of Statins Is Associated with a Reduced Risk of Mortality among Individuals with COVID-19, Zhang XJ, et al., 2020
An ALOX12–12-HETE–GPR31 signaling axis is a key mediator of hepatic ischemia-reperfusion injury, Zhang XJ, et al., 2018
Time to step-up the fight against NAFLD, Zhang XJ, et al., 2018
Targeting CASP8 and FADD-like apoptosis regulator ameliorates nonalcoholic steatohepatitis in mice and nonhuman primates, Zhang XJ, et al., 2017
The E3 ligase tripartite motif 8 targets TAK1 to promote insulin resistance and steatohepatitis, Zhang XJ, et al., 2017

Liver Injury Drug Development Chronic Liver Disease Acute Liver Disease Non-Alcoholic Fatty Liver Disease Liver Metabolism Ischemia-Reperfusion Multi-Organ Damage Pathological Mechanisms Therapeutic Targets

Pengfei Xu - Wuhan University

Jing Chen - University of Chinese Academy of Sciences

Yuanyuan Li - University of Chinese Academy of Sciences

View All

Personal Information

Academic Information

Research

Contact us

No account yet?

Personal Information

Academic Information

Research

Contact us